Trials / Completed
CompletedNCT06181786
Study of NAV-240 in Healthy Volunteers
A Randomized, Double-Blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Clinical Study to Evaluate Safety, Tolerability, and Pharmacokinetics of NAV-240 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Navigator Medicines, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of NAV-240 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NAV-240 | Intravenous administration of NAV-240 |
| DRUG | Placebo | Intravenous administration of matching placebo for NAV-240 |
Timeline
- Start date
- 2023-11-22
- Primary completion
- 2024-09-04
- Completion
- 2024-09-04
- First posted
- 2023-12-26
- Last updated
- 2025-06-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06181786. Inclusion in this directory is not an endorsement.